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Background: Malignant mesothelioma is an aggressive, treatment-resistant tumor arising from mesothelium of
pleura, peritoneum and pericardium. Despite current combined regimen, its prognosis remains dismal, calling for
more effective targeted therapies. We investigated whether aberrant Hh activation may play a role in
mesothelioma.
Methods: SMO and SHH expression levels were analyzed in 46 mesothelioma tissue specimens with real-time
RT-PCR, and correlation with survival was analyzed with univariate and multivariate Cox proportional hazards
models, Kaplan-Meier survival curves, and the log-rank test. We also examined multiple mesothelioma cell lines for
SMO expression and the effect of Hh inhibition by a specific SMO antagonist on cell proliferation by MTS assay.
Results: We observed strong correlation between higher SMO and SHH expression levels with poorer overall
survival. Remarkably, Hh inhibition by a specific SMO inhibitor significantly suppressed cell proliferation in the
mesothelioma cell lines examined.
Conclusion: Our data strongly support that Hh signaling deregulation plays critical roles in proliferation of
mesothelioma, and consistently exerts significant impact on prognosis of the disease. Therefore our findings
revealed the hitherto unappreciated role of Hh activation in mesothelioma, and pinpointed Hh signaling antagonist
as a potential new therapy against this devastating disease.
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Malignant mesothelioma is an aggressive, treatment-
resistant tumor, arising from transformed mesothelial cells
lining the pleura, peritoneum and pericardium. Athough
relatively a rare disease, its incidence rate is increasing
throughout the world [1,2]. Its major risk factor is asbestos
exposure, besides it can also be caused by ionizing radi-
ation, erionite exposure, chest injuries, and presumably
SV40 virus [3]. Patients with malignant pleural mesotheli-
oma (MPM) usually present with shortness of breath and
chest pain with pleural effusions. Patients are diagnosed* Correspondence: Biao.He@ucsfmedctr.org; natalielui22@gmail.com
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reproduction in any medium, provided the orwith cytopathology of mesothelioma effusions or fine-
needle aspirations, and histopathology is often required to
establish the diagnosis [4]. Despite the current regimen of
surgical resection, chemotherapy, and radiation therapy
for treating MPM, the prognosis remains dismal, with me-
dian survival being 9–12 months from diagnosis [3].
Therefore developing new molecular targeted therapies
may pose promise for this devastating illness.
The pathogenic mechanisms underlying mesothelioma
involve deregulation of multiple signaling pathways, includ-
ing activation of multiple receptor tyrosine kinases such as
the epidermal growth factor receptor (EGFR) family and
MET, and subsequent deregulations of mitogen-activated
protein kinase (MAPK) and phosphatidylinositol-3-kinase
(PI3K)-AKT signaling cascades, the TNF-α / NF-κB survival
pathway, Wnt signaling, and loss of tumor suppressorsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient baseline characteristics
All patients (N = 46)





















Zhang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:7 Page 2 of 8
http://www.jeccr.com/content/32/1/7such as Neurofibromatosis type 2(NF2), p16INK4A, and
p14ARF [5–7]. Understanding mechanisms of the dysregu-
lated signaling pathways allows strategies for development
of targeted new therapies against this devastating disease.
It has been recently reported that sonic hedgehog (Hh)
signaling, another important pathway during development
and tumorigenesis, is aberrantly activated in MPM, and
inhibition of hedgehog signaling suppresses tumor growth
[8]. Deregulated Hedgehog (Hh) pathway activation has
been implicated in several human cancers including gli-
oma, basal cell carcinoma, medulloblastoma, lung, breast,
pancreatic and gastric cancers [9–14]. The Hh family of
proteins controls multiple fundamental cellular functions,
including cell proliferation and survival, body patterning
and organ morphogenesis during embryonic development
[9, 13–16]. Hh signaling is orchestrated by two trans-
membrane receptors, Patched (Ptch1) and Smoothened
(SMO). In the absence of the Hh ligand, PTCH1 inhibits
SMO, causing cleavage of GLI1 to the N-terminal repressor
form. Once Hh binds to PTCH1, the inhibitory effect on
SMO is released, causing active full-length GLI1 to trans-
port into the nucleus and activate transcription of the Hh
target genes in a context- and cell-type specific manner,
including GLI1, PTCH1, HHIP and C-MYC [13–16]. Tar-
geted inhibition of aberrant Hh signaling leads to suppres-
sion of cancer stem cells awakened and propelled by
inappropriate Hh signaling [10,11,16].
We propose that the Hh signaling pathway may play an
essential role during pathogenesis of MPM. To test this
hypothesis, we measured SMO and SHH expression levels
in MPM tissue specimens, and studied the relation of
those expression levels with regard to overall survival. We
also examined multiple mesothelioma cell lines for SMO
expression and their cell proliferation responses to a spe-
cific SMO inhibitor. We therefore aim to better elucidate
the role of Hh signaling in the tumorigenesis of MPM,
and such finding may lead to development of improved
molecular targeted therapies against this fatal disease.
Methods
Patients
We identified patients who underwent surgical resection
for malignant pleural mesothelioma at our institution from
April 2000 to January 2010 and had a tissue specimen avail-
able in our tissue bank. Clinical and histological data were
obtained by review of electronic medical records and entered
prospectively into our tissue bank database. Vital status was
obtained through the Social Security Death Master File.
Overall survival was calculated from the date of surgery.
Our institutional review board approved this study.
RNA extraction and real-time RT-PCR
Total RNA was isolated from MPM tissue samples using
the RNeasy kit (Qiagen). Genomic DNA contaminationwas eliminated by DNase I treatment. 250 ng of RNA was
reverse transcribed using the iScript cDNA synthesis kit
(Bio-Rad). The resulting cDNAs were analyzed with real-
time RT-PCR using Gene Expression Assays in a 7900
Real-Time PCR System (Applied Biosystems) for 40 cycles
(96°C for 15 seconds and 60°C for 1 minute). Gene expres-
sions were normalized to 18S rRNA expression.Immunohistochemistry (IHC)
Peroxidase-based immunohistochemistry using paraffin-
sections was performed per standard protocol. Smo anti-
body (abcam, ab72130) and Shh antibody (abcam, ab19897)
were employed following the manufacturer's instructions.
These slides were then mounted in Citifluor.Cell lines and cell culture
Mesothelioma cell lines NCI-H28, REN, and H290 were
cultured in RPMI 1640 (Life Technology, Carlsbad, CA)
supplemented with 10% FBS and penicillin (100 IU/ml)
and streptomycin (100 ug/ml), at 37°C in a humid incu-
bator with 5% CO2. Cells were seeded one day before
treatment with cyclopamine (Selleckchem) at 10 uM and
20 uM or vehicle (DMSO) for 72 hours. Cells were sub-
jected to proliferation assays at 0, 24, 48 and 72 hours
after drug treatment.
Figure 1 IHC analysis of Smo protein expression in mesothelioma tissue samples. A-C: Representative images of IHC for evaluating Smo
protein expression level with score of 1,2 and 3. A, 1-low level; B, 2-intermediate level; C, 3-high level. D, RT-PCR measuring Smo mRNA
expression level of corresponding samples of 1–3 as in A-C.
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Cells will be treated with Cyclopamine at indicated doses in
96-well plates for 6–7 days. Cell proliferation was assayed
by MTS assay (Promega) according to the manufacturer’s
protocol and as described previously [17]. The quantity of
formazan product as measured by the absorbance at
490 nm is directly proportional to the number of living cells
in culture. Data are representative of at least 3 independent
experiments with similar results.
Western blotting
Whole cell lysates were resolved by SDS-PAGE and
transferred to nitrocellulose membranes for immuno-
blotting with the indicated antibodies: α-human SMO
mouse monoclonal antibody (Sigma), α-ß-actin mouse
monoclonal antibody (Sigma) as described previously
[18]. Data represent three independent experiments
with consistent results.
Survival and statistical analyses
Survival analysis was performed using univariate and
multivariate Cox proportional hazards models, Kaplan-
Meier survival curves, and the log-rank test. For the Cox
proportional hazards models, age and sex were includedin the multivariate model a priori. Race, histological
type, stage, smoking status were included in the multi-
variate model only if the p-value was less than 0.10 in
the univariate analysis. For all statistical tests, a two-
sided alpha level less than 0.05 was considered statisti-




Forty-six patients underwent surgical resection for ma-
lignant pleural mesothelioma at our institution, had tis-
sue specimens deposited at our tissue bank and available
for use. Patient baseline characteristics were summarized
as in Table 1.
SMO and SHH expression analysis
SMO and SHH expression levels were evaluated at both
mRNA and protein expression levels. Protein expres-
sion levels examined by Immunohistochemistry (IHC)
correlated well with mRNA levels assessed by RT-PCR
(examples are shown in Figure 1). SMO expression level
was determined for all 46 patients, whereas SHH ex-
pression level was determined for 23 patients. Since
Table 2 Univariate and multivariate Cox proportional hazards model
Univariate analysis Multivariate analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age (10 years) 0.84 0.61-1.16 0.28 0.82 0.57-1.17 0.28
Sex
Female 1 1
Male 0.55 0.27-1.12 0.10 0.75 0.33-1.74 0.50
Histologic type
Epithelioid 1 0.04 1 0.08
Sarcomatous 7.76 1.54-39.0 0.01 7.26 1.25-42.1 0.03
Other 1.53 0.58-4.00 0.39 1.38 0.52-3.69 0.52
SMO expression level 1.05 1.00-1.10 0.05 1.06 1.00-1.12 0.03
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wide range, we chose the median level from the tumor
samples as a good initial threshold to investigate the im-
portance of SMO and SHH. Separated apart by the me-
dian level, 23 (50%) samples above the median were named
as the "high" category, while 23 (50%) samples below the
median were named as the "low" category. The number ofFigure 2 Kaplan-Meier survival curves by (A) sex, (B) race, (C) smokinsamples in each category is displayed in the risk table below
each Kaplan-Meier survival curve.
Survival analysis
Median follow-up time was 11.8 months (inter-quartile
range, 6.3 to 27.0 months). Forty-five patients died, in-
cluding 31 patients who died within two years of theirg status, and (D) histological type.
Figure 3 Kaplan-Meier survival curves by (A) SMO and (B) SHH expression levels.
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model, sex and histological type were significantly asso-
ciated with overall survival, and these variables were
included in the multivariate model (Table 2). Age was not
significantly associated with overall survival, however, this
variable was included in the multivariate model a priori.
Race, smoking status, and stage were not significantly asso-
ciated with overall survival, and these variables were not
included in the multivariate model. In the univariate
model, higher SMO expression levels were associated with
worse overall survival (p = 0.05). Kaplan-Meier survival
estimates confirmed these results (Figures 2 and 3A).
In the multivariate Cox proportional hazards model,
SMO expression level remained associated with worse sur-
vival (Table 2). However, sex was no longer associated with
overall survival (p = 0.50) and histological type was less
strongly associated with overall survival (p = 0.08). AfterFigure 4 Quantitative RT-PCR analysis of Shh pathway effectors in me
with 15 uM cyclopamine for 72 hrs. RNA was then collected for cDNA synt
for normalization.adjusting for age, sex, and histological type, the hazard
ratio and significance of SMO expression level increased
compared to the univariate model (p = 0.03).
SHH expression level was analyzed separately because
data was only available for 26 patients. In the univariate
model, SHH expression level was significantly asso-
ciated with overall survival. Increase in SHH expression
level strongly correlates with elevated risk of death (95% CI,
1-28%; p = 0.04; data not shown). When SHH expression
level was dichotomized at the median, log-rank test was
not significant (p = 0.45), although the Kaplan-Meier sur-
vival curve showed separation after 12 months (Figure 3B).
After including SHH expression level in the multivariate
model above, SHH expression level remained significant
and even increased the significance of SMO expression
level. After adjusting for age, sex, and histological type,
increase in SMO expression level strongly correlatessothelioma cell lines treated with cyclopamine. Cells were treated
hesis and quantitative PCR. Actin was used as an internal control
Figure 5 Analysis of SMO expression and function in mesothelioma cell lines. (A) Western analysis of SMO expression in mesothelioma cell
lines. (B-D) MTS proliferation assay of mesothelioma cell lines following SMO inhibitor cyclopamine treatment.
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data not shown); and so does increase in SHH expres-
sion level (95% CI, 1-26%; p = 0.04; data not shown).
Histological type was no longer associated with overall
survival (p = 0.87).Figure 6 Real-time RT-PCR analysis of expression level of (A) SMO an
expression level of SMO (A) or SHH (B) mRNA (arbitrary units). Y-axis represSMO Inhibition suppresses mesothelioma cell
proliferation
To assess the role of Hh signaling in tumor growth of
mesothelioma, we utilized a small molecule Hh signal-
ing inhibitor cyclopamine which specifically antagonizesd (B) SHH in MPM tissue samples. X-axis represents Relative
ents percentage of the MPM tissue samples analyzed.
Zhang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:7 Page 7 of 8
http://www.jeccr.com/content/32/1/7SMO receptor [11]. Three mesothelioma cell lines were
treated with cyclopamine and examined for expression
of several key effectors of the SHH pathway. Expression
of all Gli downstream effector genes (including GLI1,
GLI2, PTCH, PTCH2) was suppressed, suggesting the
specificity of cyclopamine in inhibiting the SHH path-
way (Figure 4).
We observed relatively high level of endogenous SMO
expression in all three mesothelioma cell lines examined,
including H28, H290 and REN (Figure 5A). Notably,
Cyclopamine treatment significantly suppressed prolifera-
tion of these mesothelioma cells in a dose-dependent
manner (Figure 5B-D). These results strongly support that
Hh signaling plays essential role in mesothelioma cell
proliferation.Role of Hh activation in mesothelioma
Hh signaling plays pivotal roles in development and in can-
cer. It is implicated in tumorigenesis of multiple human
cancers. However, whether Hh signaling plays essential
roles in mesothelioma remains elusive. We have analyzed
both mRNA and protein expression profiles of mesothe-
lioma tumor samples from 46 patients, and showed that
SHH and SMO expression was spreading over a wide
range of expression levels (Figure 6). To assess whether
Hh signaling activation may impact on the prognosis of
mesothelioma patients, we carried out univariant and mul-
tivariant COX proportional hazard ratio analysis. Interest-
ingly, we observed that higher SMO expression levels are
strongly associated with worse overall survival in malignant
pleural mesothelioma after adjusting for age, sex, and histo-
logical type (Figures 2, 3A). Consistently, higher SHH ex-
pression level correlates with worse survival in a smaller
number of patients (Figure 3B). Although our results are
limited by relatively small number of patients, due to the
relatively low incidence of MPM, our data strongly support
that Hh signaling plays indispensable roles in mesotheli-
oma, and exerts significant impact on the prognosis of
mesothelioma patients.
As deregulated Hh signaling pathway has been impli-
cated in many different types of cancer, and inhibition of
Hh signaling leads to suppression of tumor growth
[10,11], we addressed whether Hh signaling plays critical
roles in proliferation of mesothelioma cells. Remarkably,
we observed elevated endogenous SMO expression in
3 mesothelioma cell lines tested (Figure 5A). Furthermore,
utilizing a specific Hh inhibitor cycloplamine, which sig-
nificantly suppressed expression of Gli downstream targets
(Figure 4), we observed significant inhibition of cell pro-
liferation in all 3 mesothelioma cell lines examined
(Figure 5B-D). These data indicate that aberrant Hh activa-
tion plays critical roles in tumor cell proliferation in meso-
thelioma, consistent with recent data by Shi Y et al. [8].Conclusions
Taken together, our results demonstrated a strong asso-
ciation between higher SMO and SHH expression levels
with poorer overall survival. Furthermore, we showed in-
hibition of Hh signaling blocked cell proliferation in
multiple mesothelioma cell lines, strongly supporting
that aberrant Hh signaling is essential for tumor growth
in mesothelioma. Therefore our findings revealed the
hitherto unappreciated roles of Hh activation in MPM,
and pinpointed Hh signaling antagonist as a potential
new therapy against this devastating disease.
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